Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Moleculin Biotech, Inc. (MBRX)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research & development | $15.9M | $17.7M | $19.5M | $19.0M | $14.4M | $12.8M | $11.0M | $9.7M | $4.5M | $1.5M |
| Operating expenses | $25.1M | $26.6M | $29.6M | $30.6M | $23.0M | $19.7M | $17.5M | $15.0M | $8.7M | $3.9M |
| Operating income | −$25.1M | −$26.6M | −$29.6M | −$30.6M | −$23.0M | −$19.7M | −$17.5M | −$15.0M | −$8.7M | −$3.9M |
| EBITDAderived | −$25.0M | −$26.5M | −$29.5M | −$30.5M | −$22.8M | −$19.5M | −$17.3M | −$15.0M | −$8.6M | −$3.9M |
| Net income | −$33.6M | −$26.0M | −$29.8M | −$29.0M | −$15.9M | −$17.4M | −$13.2M | −$11.9M | −$9.8M | −$3.9M |
| Basic EPSper diluted share | -$28.42 | -$189.14 | -$15.07 | -$15.22 | -$0.59 | -$1.76 | -$1.95 | -$0.46 | -$0.53 | -$0.40 |
| Diluted EPSper diluted share | — | — | — | — | -$0.59 | -$1.76 | -$1.95 | -$0.46 | -$0.53 | -$0.40 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 23, 2025Form 4 | Foster Jonathan P.Chief Financial Officer | BuyCommon Stock | 270.3K | $0.37 | $100.0K | 287.6K |
| Jun 23, 2025Form 4 | Foster Jonathan P.Chief Financial Officer | BuySeries E Warrants · derivative | 810.8K | — | — | 1.04M |
| Jun 23, 2025Form 4 | KLEMP WALTER VCEO and President | BuyCommon Stock | 675.7K | $0.37 | $250.0K | 743.6K |
| Jun 23, 2025Form 4 | KLEMP WALTER VCEO and President | BuySeries E Warrants · derivative | 2.03M | — | — | 2.41M |